UPS announced a $48 million investment in 27 temperature-controlled freight cross-dock facilities globally. The facilities are located in key U.S. and international markets, including Europe, Asia, and the Americas, and are designed to support faster, more visible, and more controlled movement of temperature-sensitive healthcare products.
The facilities are optimized for speed and short-term storage between air and ground movements while maintaining specific temperature requirements. UPS said the investment strengthens its global cold-chain network as demand grows for medicines requiring strict temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius, and frozen.
According to Growth Market Reports, industry demand for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate through 2033, reaching an estimated $39.1 billion. UPS said meeting this demand requires cold-chain expertise to maintain product quality and safety from manufacturing to the patient.
UPS said the 27 temperature-controlled freight cross-docks are designed to create seamless movement across transportation modes. The facilities are compliant with IATA CEIV Pharma certification, an industry-recognized standard for pharmaceutical handling and quality. The integrated network is intended to reduce provider handoffs, increase control, protect high-value therapies from temperature excursions and disruptions, and support real-time monitoring through a 24/7/365 control tower.
The investment comes as biologics, cell and gene therapies, mRNA platforms, GLP-1 injectables, and other advanced treatments increase the complexity of healthcare logistics. UPS cited PharmaSource data indicating that about one in three newly approved drugs today is a biologic, with more than 85% of those requiring temperature-controlled handling. Cold-chain failures are estimated to cost up to $35 billion annually and contribute to up to 50% of global vaccine waste, according to cited industry and WHO data.
UPS’s cross-dock expansion builds on its broader investment in complex healthcare logistics, including acquisitions such as Bomi Group, Frigo Trans and BPL in Europe, and Andlauer Healthcare Group in North America. UPS also recently expanded its Incheon, Korea air hub to support growing pharmaceutical trade flows.
KEY QUOTES:
“We have aligned our investments with our Healthcare customers’ specialized needs. Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world. This effort – and all of our work in healthcare logistics – extends from a deep understanding that we’re doing more than moving packages. We are helping patients access the medications and treatments they need.”
Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS
“Biologics and personalized treatments are driving better, more targeted care for patients. These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes.”
John Bolla, President of UPS Healthcare
